Catalent, Inc. (NYSE:CTLT) Receives Average Rating of “Hold” from Brokerages

Shares of Catalent, Inc. (NYSE:CTLT) have received a consensus rating of “Hold” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation. The average 1 year target price among brokerages that have covered the stock in the last year is $59.83.

Several equities analysts have commented on CTLT shares. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Barclays increased their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th.

Insiders Place Their Bets

In related news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,410 shares of company stock worth $732,680 over the last three months. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Hedge funds and other institutional investors have recently bought and sold shares of the company. Gamco Investors INC. ET AL boosted its stake in shares of Catalent by 403.3% during the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after purchasing an additional 20,273 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Catalent by 2,792.9% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after buying an additional 498,540 shares during the last quarter. UniSuper Management Pty Ltd raised its holdings in Catalent by 509.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock valued at $1,028,000 after buying an additional 15,217 shares during the last quarter. Swedbank AB bought a new position in Catalent in the 1st quarter valued at approximately $1,659,000. Finally, SG Americas Securities LLC grew its holdings in Catalent by 147.4% during the 1st quarter. SG Americas Securities LLC now owns 99,588 shares of the company’s stock worth $5,622,000 after acquiring an additional 59,339 shares during the last quarter.

Catalent Trading Down 0.4 %

Shares of NYSE:CTLT opened at $60.45 on Friday. The company has a 50-day simple moving average of $60.03 and a 200 day simple moving average of $57.65. The company has a market capitalization of $10.94 billion, a P/E ratio of -9.91, a price-to-earnings-growth ratio of 2.14 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent has a 52-week low of $31.80 and a 52-week high of $61.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. Sell-side analysts forecast that Catalent will post 0.95 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.